1-4 of 4
Grzegorz S. Nowakowski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

Open Access
Grzegorz S. Nowakowski, Dok Hyun Yoon, Anthea Peters, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E. Waltl, Mark Winderlich, Nuwan C. Kurukulasuriya, Sumeet Ambarkhane, Georg Hess, Gilles Salles
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4003–4017.
https://doi.org/10.1158/1078-0432.CCR-21-3648
Published: 15 September 2022
View articletitled, Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Open the PDF for Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study in another window
Includes: Supplementary data
Journal Articles

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Open Access
Pier Luigi Zinzani, Thomas Rodgers, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, Nathan H. Fowler, Gilles Salles, Bruce Feinberg, Nuwan C. Kurukulasuriya, Sascha Tillmanns, Stephan Parche, Debarshi Dey, Günter Fingerle-Rowson, Sumeet Ambarkhane, Mark Winderlich, Grzegorz S. Nowakowski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6124–6134.
https://doi.org/10.1158/1078-0432.CCR-21-1471
Published: 15 November 2021
View articletitled, RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Open the PDF for RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma

Free
Jacob P. Smeltzer, Jason M. Jones, Steven C. Ziesmer, Deanna M. Grote, Bing Xiu, Kay M. Ristow, Zhi Zhang Yang, Grzegorz S. Nowakowski, Andrew L. Feldman, James R. Cerhan, Anne J. Novak, Stephen M. Ansell
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 2862–2872.
https://doi.org/10.1158/1078-0432.CCR-13-2367
Published: 29 May 2014
View articletitled, Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma
Open the PDF for Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma in another window
Journal Articles

A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer

Free
Grzegorz S. Nowakowski, Andrea K. McCollum, Matthew M. Ames, Sumithra J. Mandrekar, Joel M. Reid, Alex A. Adjei, David O. Toft, Stephanie L. Safgren, Charles Erlichman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (20): 6087–6093.
https://doi.org/10.1158/1078-0432.CCR-06-1015
Published: 24 October 2006
View articletitled, A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer in another window